AmplifiDx, founded in 2020 and headquartered in Pleasanton, California, is dedicated to developing affordable, high-performance molecular point of care devices. Their core mission is to provide accessible and efficient diagnostic solutions that combine visual appeal with ease of use and low cost. The company's flagship product, the DX1000, is engineered for fast turnaround and high sensitivity, delivering clear and actionable COVID-19 results directly to connected mobile devices within minutes. AmplifiDx aims to revolutionize point of care diagnostics by offering laboratory-grade performance in a portable format.

Notable figures affiliated with AmplifiDx include key industry experts and investors who have supported the company's rapid growth and innovation. Since its inception, AmplifiDx has achieved significant milestones, including the successful development and deployment of the DX1000 during the COVID-19 pandemic. Their technology has had a substantial impact on public health by enabling quick isolation of infected individuals, thereby helping to curb the spread of the virus. AmplifiDx continues to push the boundaries of point of care diagnostics, making high-quality healthcare more accessible worldwide.